医学
吉西他滨
内科学
恶性肿瘤
危险系数
胃肠病学
淋巴结
胰十二指肠切除术
胰腺癌
辅助治疗
肿瘤科
腺癌
胰腺
癌症
置信区间
作者
Cecilia G. Ethun,Alexandra G. Lopez‐Aguiar,Timothy M. Pawlik,George A. Poultsides,Kamran Idrees,Ryan C. Fields,Sharon M. Weber,Clifford Cho,Robert C.G. Martin,Charles R. Scoggins,Perry Shen,Carl Schmidt,Ioannis Hatzaras,David J. Bentrem,Syed A. Ahmad,Daniel E. Abbott,Han Jo Kim,Nipun B. Merchant,Charles A. Staley,David A. Kooby
标识
DOI:10.1016/j.jamcollsurg.2016.12.006
摘要
Distal cholangiocarcinoma and pancreatic ductal adenocarcinoma are distinct entities. Distal cholangiocarcinoma has a favorable prognosis compared with PDAC, yet current adjuvant therapy regimens are only associated with improved survival in PDAC, not DC. Therefore, treatment paradigms used for PDAC should not be extrapolated to DC, despite similar operative approaches, and novel therapies for DC should be explored.
科研通智能强力驱动
Strongly Powered by AbleSci AI